
The silent surge: Early onset of chronic illnesses
Across India's sprawling office complexes, sleek co-working hubs, and hybrid home workspaces, a health crisis is silently unfolding. While much attention is focused on digital disruption, AI transformation, and skilling for the future, an equally urgent, less recognised, and under-discussed crisis is taking root: the early onset of chronic illnesses among working Indians, often a decade earlier than seen globally..The Employee Health Report 2025, by Plum, analysed data from over 100,000 telehealth consultations, 25,000 insurance claims, 1,998 health camp participants, and 512 survey responses across 6,000+ companies. The report reveals a stark reality: chronic health conditions such as diabetes, hypertension, cardiovascular diseases, and mental health disorders are now manifesting by the age of 35 or even earlier in India's salaried class. For a nation staking its future on its demographic dividend, this is both an economic and social red flag. What it signifies is a decade of lost health. In most developed countries, lifestyle-related chronic conditions tend to show up post-age -50, giving people a full three decades of stable employment productivity before grappling with health setbacks. But in India, the average age of onset has slid into the thirties, even the late twenties. What is alarming is the intensity and clustering of these diseases: comorbidities are becoming the norm rather than the exception..Rethinking mental health at workplace.The report highlights that nearly 20% of urban white-collar workers in India suffer from multiple chronic ailments. Worse still, mental health issues are surging, with 1 in 5 employees having sought professional help, and 1 in 5 considering quitting due to burnout. This is just the data captured from insured employees, an urban upper crust. The figures among gig workers, contractual staff, and MSME employees – most without insurance or workplace wellness programmes – would be worse..Three factors are driving this premature health decline: First, ironically, is the nature of work itself. India's service economy, powered by IT, finance, education, media, and e-commerce, leans heavily on sedentary desk jobs. With the rise of remote work, digital presence has replaced physical exertion. Employees routinely clock 10-12-hour days, eyes glued to screens, meals skipped or hastily eaten, and movement limited to keystrokes and Zoom calls..Second, a growing urban disconnect from wellness. In metropolitan areas, access to green spaces, safe pedestrian infrastructure, or time for leisure activity is shrinking. Long commutes, overcrowding, and pollution aggravate physical inactivity and highly processed, delivery-based food makes a recipe for metabolic disorders..Third, is the phenomenon of cultural stigma and denial. In workplaces, chronic fatigue, burnout, or depression are often dismissed as a 'phase', a lack of willpower, or even laziness. This stigma drives employees to delay seeking care. Until they crash..Common mental health problems are growing. What is unfolding is not just a physical health crisis, but a psychological one. Burnout is no longer a buzzword; it is a lived reality. Employees report symptoms ranging from insomnia and anxiety to persistent demotivation and even clinical depression. Managers are often unable to identify or act upon these red flags, partly due to a lack of training and outdated assumptions about 'professionalism.' This is made worse by the demand for longer work hours. Unlike physical illnesses that have defined markers and treatment paths, mental health disorders are murkier and harder to quantify – making them both widespread and dangerously under-treated..The economic costs of this invisible but growing health challenge are inescapable. Chronic illnesses are not just private tragedies – they are societal economic liabilities. A workforce beset by hypertension or stress is less productive, more prone to absenteeism, and more likely to switch jobs frequently. For companies, this translates into spiralling health insurance claims, lost person-hours, and increasing employee turnover. At a macro level, the early onset of chronic diseases shortens productive work lives, potentially flattening India's much-touted demographic dividend. For a country hoping to leverage its young population to power global growth engines, this is akin to trying to sprint on a sprained ankle..Shift in approach.There is a need for a new paradigm of workplace health. We can no longer afford to treat employee health as a side benefit or a corporate box-ticking exercise. We need a fundamental shift in how workplaces think about health – from reactive treatment to initiative-taking well-being. What might such a shift look like?.Institutionalising preventive health checks: Annual health screenings, biometric risk assessments, and lifestyle counselling should become default offerings. These should be mandated and subsidised, particularly in sectors like IT, finance, and logistics..Designing movement into the workday: Standing desks, stretch breaks, walking meetings, and ergonomic workplace design can go a long way in reducing the toll of sedentary lifestyles. Urban planners and architects too must rethink the live-work-commute model..Mental health first aid: Companies must not only offer access to mental health professionals but actively normalise the use of these services. Mental health sick days, manager sensitisation workshops, and peer support groups must be institutionalised..Government and policy: Just as CSR mandates funding social causes, a small percentage of profits could be directed to health and wellness infrastructure, including access to gym memberships, therapy, and nutrition..It is time to address the rapid epidemiological transition from communicable diseases to non-communicable diseases in both urban and rural India. The early onset of chronic diseases must receive dedicated attention through awareness and surveillance mechanisms. Employers, policymakers, and healthcare providers must collaborate to foster a culture that prioritises health and well-being.The data is clear. The trend is urgent. The impact is generational. Investing in employee health is not just an economic necessity but a moral imperative. Our greatest asset – human capital – must not become our greatest vulnerability..(The writer is the Director of School of Social Sciences, Ramaiah University of Applied Sciences)

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
3 hours ago
- Economic Times
One cough too many: India's TB fight isn't quite there yet
Agencies A PIB release dated March 24, 2025, says India's TB elimination targets for 2025 are an 80% reduction in incidence and a 90% reduction in deaths, compared with 2015. One moment Anushka (name changed) was a college student. Then her world turned upside down. It started with a persistent cough and high fever. Despite popping meds, it wouldn't go away. Tests followed and then came the news that knocked the stuffing out of her—she had a fatal form of tuberculosis (TB). With scarred lungs, she gasped for each breath. The bacteria had killed her appetite, making her frail and bony. Her skin colour changed—to dark and then grew paler. At 20, her life expectancy dwindled to a few months.'I felt weak,' she recalls, 'and preferred to be alone.'Battling extensively drug-resistant tuberculosis or XDR-TB, a form of the disease in which drugs rarely worked, Anushka's only option was to be loaded each day with scores of tablets and injections. Those came with toxic side effects. For over four years, she moved between government and private hospitals, enduring cycles of failed treatment. Relief came only when she was placed on a salvage regimen—the last option when all other interventions are exhausted—at a Médecins Sans Frontières (MSF) clinic in Govandi, Mumbai. The global humanitarian group offered Anushka a cocktail of bedaquiline, delamanid and imipenem injections, a set of very powerful meds often inaccessible to most Indians due to supply restrictions aimed at curbing drug resistance. Anushka, who has now recovered, recounted her ordeal at MSF's TB Day event in Mumbai on May 12, speaking before an audience of doctors, a quiet smile breaking through years of pain. Her journey to recovery is rare, and alien to millions in India, which reflects a public health system still failing its most vulnerable. India now accounts for more than a quarter of all TB cases reported worldwide. In 2023, the country had 26% of the global TB burden, according to the World Health Organization (WHO). Bending the curve remains difficult despite multiple national programmes. How can India improve?In 2018, when India pledged to eliminate TB by 2025, five years ahead of the set global target, the objective was clear. And progress has been made, too. Between 2015 and 2023, TB incidence (new and relapsed cases per 1 lakh population every year) fell by 18% and deaths by 24%, per is a sign in the right direction, but the number of cases are still astounding, especially when it comes to drug-resistant variants. 'India bears the highest burden of XDR-TB globally, with an estimated 110,000 new cases annually,' says Professor Anil Koul of the London School of Hygiene and Tropical Medicine. A key figure in TB drug research, Koul was part of a Johnson & Johnson team that developed bedaquiline, one of the most effective drugs against resistant TB notes that Covid-19 deepened the crisis, and underfunded research has stalled progress. Of the 27 drugs in clinical trials, none have reached Phase III. Bedaquiline remains the mainstay.A 100-day TB Elimination Challenge was launched by the government in December 2024 to amplify efforts to diagnose and treat TB at the village level, but experts aren't satisfied.'We are not on track,' says Dr Animesh Sinha, chronic care and infectious disease advisor, MSF. 'To meet the 2025 milestones of WHO's End TB strategy, India should achieve a 50% reduction in TB incidence rate and a 75% reduction in the total number of TB deaths compared with 2015.' Although numbers have fallen, the quantum has been woefully short of the target, as WHO numbers suggest.A PIB release dated March 24, 2025, says India's TB elimination targets for 2025 are an 80% reduction in incidence and a 90% reduction in deaths, compared with 2015.A key problem is underreporting emanating from under-diagnosis. India's notification rate (number of TB cases diagnosed and officially reported) has improved from 108 per 100,000 population in 2010 to 166 in 2023, yet many cases, especially in rural areas, go undetected.'In order to address the TB crisis, we have to find the missing cases,' says Sinha. Nonetheless, the 2025 goal helped push TB up the political agenda. Ni-kshay, a digital platform for notification and treatment monitoring, is improving reporting. But without proportionate investment in diagnostics, staffing and drug access, the pace of progress will be inconsistent. Intermittent drug shortages have been reported, and India spent just 2.1% of the National Tuberculosis Elimination Programme budget on diagnostics till 2023-24, an IndiaSpend RTI revealed. 'The 2025 target was always a stretch,' says Koul. 'But it did galvanise government machinery, leading to faster approvals for newer regimens like bedaquiline, speedier rollout across TB centres and more budgetary support, including for nutritional aid.'That said, TB continues to receive only a sliver of public health funding. But even so, he notes, there certainly is a positive trend in fighting back, considering the complexity of the disease and the socioeconomic factors shaping in an ET Morning Brief podcast in January, Dr Urvashi Singh, deputy director-general (TB), Ministry of Health and Family Welfare, said, 'The domestic budget for the national TB programme has increased over five times in the last 10 years.' India, she added, is the only high-burden country where 91% of the programme is backed by domestic detection is often the difference between quick recovery and years of suffering. Goa-based diagnostic device maker Molbio Diagnostics' Truenat, a portable molecular-testing platform, introduced in 2017, expanded diagnostic access, particularly in low-access regions. 'We supplied over 90 lakh testing kits last year and expect to provide 1.25 crore this year,' says Sriram Natarajan, CEO of Molbio, which is working with government and statelevel partners to rollout molecular testing.A Truenat test costs just Rs 640, a fraction of what imported diagnostics demand, says Natarajan. In public health, he argues, the real measure isn't price, but cost-effectiveness, especially when early detection can avert far greater globally approved diagnostics protocols remain out of reach in India. The WHO-recommended urine TBLAM test, used to diagnose TB in HIVpositive patients, is still unavailable in the country, despite successful validation studies in Mumbai in 2022. Registration barriers and lack of supply from manufacturers have led to lack of access, says Leena Menghaney, a public health lawyer based in Delhi. Supplyrelated issues could be because trials in India have yet to conclude, according to industry delays cost precious lives. Late detection risks high transmission rates and complications for patients. Dr Jennifer Furin, infectious diseases clinician, Harvard Medical School, says while Truenat is helpful and the diagnostic pipeline is robust, the outdated and slow systems for approving novel tools in India have a detrimental impact. Furin points to a critical gap: the lack of household-level prevention. Studies, including a 2023 trial published in TheLancet, show that modest nutritional support for families of TB patients can sharply reduce transmission. Another model, published in TheLancet this year, estimates that improving household nutrition alone could prevent nearly 5% of TB deaths by carrying the world's highest TB burden, regulatory reforms have been slow in India. Some gains have been made, but systemic delays continue to blunt the impact of new patients with drug-resistant TB, a new wave of treatment offers hope, but conditions apply. Regimens like a six-month, all-oral combination termed BPaLM— bedaquiline, pretomanid, linezolid and moxifloxacin—have been game-changers, replacing the gruelling 24-month regimens of daily injections and pills. 'These regimens are better tolerated and highly effective, with about 90% of people completing treatment successfully,' says Sinha. While clinicians welcome the government's push for shorter regimens, access remains limited—only 1,700 patients in India have received them, according to Dr Rupak Singla, head of the department of respiratory medicine, National Institute of Tuberculosis and Respiratory Diseases, Delhi, who spoke at the event in Mumbai. Adoption has lagged due to limited access to drug susceptibility testing for newer drugs, which is crucial for choosing an appropriate treatment strategy. The BPaLM regimen can't be given in cases where more than one organ system is involved or in patients with severe extrapulmonary disease, 'both of which are common in India,' according to Dr Alpa Dalal, head of unit, Group of TB Hospitals, Sewri, Mumbai. BPaLM should not be prescribed for patients previously treated with bedaquiline, says Dalal, unless drug susceptibility to bedaquiline and linezolid is says even in extensive pulmonary TB, where studies have shown good outcomes with BPaLM, many clinicians are cautious. In longer regimens, patients with extensive lung involvement have had higher relapse rates, compared with patients with limited disease, she explains, and that concern carries over. A study published in OUP's research platform, Oxford Academic, in March 2025 shows that bedaquiline resistance among previously treated patients can reduce the drug's warn that such resistance could undercut its effectiveness in the long term if not addressed early. But Koul says, 'Bedaquiline has galvanised TB R&D. It will remain a core component of future regimens, unless we see a dramatic rise in resistance in clinical practice.'The economics of care create barriers too. Pricing is a big hurdle. Regimens with imipenem cost thousands of rupees per day. Anushka was treated free by MSF. Else each injection alone, she said, would cost Rs 2,499. Considering the socioeconomic realities of India, perhaps this is where the government could step approach to procurement is problematic too. The country selectively joins pooled procurement platforms like the Global Drug Facility, which could reduce costs. 'India has in the past refused to participate in this, unless they had an emergency,' says policy and procurement, TB is a profoundly social disease, shaped by stigma, poverty and undernutrition. Even the best drugs won't work if care doesn't reach those who need it most. Guidelines may improve and approvals may accelerate but until the system meets people where they are, too many will be left suffered for years before she got cured. Her strength wasn't just in surviving; it was in refusing to give up. 'Even in that condition, I completed my graduation and kept chasing my dreams,' she says. India's TB response must now rise to match that grit, with urgency, equity and compassion.


Time of India
4 hours ago
- Time of India
One cough too many: India's TB fight isn't quite there yet
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads MISSING CASES Tired of too many ads? Remove Ads NEW HOPE, OLD GAPS A CURE WITH ISSUES WHAT NEXT? One moment Anushka (name changed) was a college student. Then her world turned upside down. It started with a persistent cough and high fever. Despite popping meds, it wouldn't go away. Tests followed and then came the news that knocked the stuffing out of her—she had a fatal form of tuberculosis TB ). With scarred lungs, she gasped for each breath. The bacteria had killed her appetite, making her frail and bony. Her skin colour changed—to dark and then grew paler. At 20, her life expectancy dwindled to a few months.'I felt weak,' she recalls, 'and preferred to be alone.'Battling extensively drug-resistant tuberculosis or XDR-TB, a form of the disease in which drugs rarely worked, Anushka's only option was to be loaded each day with scores of tablets and injections. Those came with toxic side effects. For over four years, she moved between government and private hospitals, enduring cycles of failed came only when she was placed on a salvage regimen—the last option when all other interventions are exhausted—at a Médecins Sans Frontières (MSF) clinic in Govandi, Mumbai. The global humanitarian group offered Anushka a cocktail of bedaquiline , delamanid and imipenem injections, a set of very powerful meds often inaccessible to most Indians due to supply restrictions aimed at curbing drug who has now recovered, recounted her ordeal at MSF's TB Day event in Mumbai on May 12, speaking before an audience of doctors, a quiet smile breaking through years of pain. Her journey to recovery is rare, and alien to millions in India, which reflects a public health system still failing its most vulnerable. India now accounts for more than a quarter of all TB cases reported worldwide. In 2023, the country had 26% of the global TB burden, according to the World Health Organization (WHO). Bending the curve remains difficult despite multiple national can India improve?In 2018, when India pledged to eliminate TB by 2025, five years ahead of the set global target, the objective was clear. And progress has been made, too. Between 2015 and 2023, TB incidence (new and relapsed cases per 1 lakh population every year) fell by 18% and deaths by 24%, per is a sign in the right direction, but the number of cases are still astounding, especially when it comes to drug-resistant variants. 'India bears the highest burden of XDR-TB globally, with an estimated 110,000 new cases annually,' says Professor Anil Koul of the London School of Hygiene and Tropical Medicine. A key figure in TB drug research, Koul was part of a Johnson & Johnson team that developed bedaquiline, one of the most effective drugs against resistant TB notes that Covid-19 deepened the crisis, and underfunded research has stalled progress. Of the 27 drugs in clinical trials, none have reached Phase III. Bedaquiline remains the mainstay.A 100-day TB Elimination Challenge was launched by the government in December 2024 to amplify efforts to diagnose and treat TB at the village level, but experts aren't satisfied.'We are not on track,' says Dr Animesh Sinha, chronic care and infectious disease advisor, MSF. 'To meet the 2025 milestones of WHO's End TB strategy, India should achieve a 50% reduction in TB incidence rate and a 75% reduction in the total number of TB deaths compared with 2015.' Although numbers have fallen, the quantum has been woefully short of the target, as WHO numbers suggest.A PIB release dated March 24, 2025, says India's TB elimination targets for 2025 are an 80% reduction in incidence and a 90% reduction in deaths, compared with 2015.A key problem is underreporting emanating from under-diagnosis. India's notification rate (number of TB cases diagnosed and officially reported) has improved from 108 per 100,000 population in 2010 to 166 in 2023, yet many cases, especially in rural areas, go undetected.'In order to address the TB crisis, we have to find the missing cases,' says Sinha. Nonetheless, the 2025 goal helped push TB up the political agenda. Ni-kshay, a digital platform for notification and treatment monitoring, is improving reporting. But without proportionate investment in diagnostics, staffing and drug access, the pace of progress will be drug shortages have been reported, and India spent just 2.1% of the National Tuberculosis Elimination Programme budget on diagnostics till 2023-24, an IndiaSpend RTI revealed.'The 2025 target was always a stretch,' says Koul. 'But it did galvanise government machinery, leading to faster approvals for newer regimens like bedaquiline, speedier rollout across TB centres and more budgetary support, including for nutritional aid.'That said, TB continues to receive only a sliver of public health funding. But even so, he notes, there certainly is a positive trend in fighting back, considering the complexity of the disease and the socioeconomic factors shaping in an ET Morning Brief podcast in January, Dr Urvashi Singh, deputy director-general (TB), Ministry of Health and Family Welfare, said, 'The domestic budget for the national TB programme has increased over five times in the last 10 years.' India, she added, is the only high-burden country where 91% of the programme is backed by domestic detection is often the difference between quick recovery and years of suffering. Goa-based diagnostic device maker Molbio Diagnostics' Truenat, a portable molecular-testing platform, introduced in 2017, expanded diagnostic access, particularly in low-access regions. 'We supplied over 90 lakh testing kits last year and expect to provide 1.25 crore this year,' says Sriram Natarajan, CEO of Molbio, which is working with government and statelevel partners to rollout molecular testing.A Truenat test costs just Rs 640, a fraction of what imported diagnostics demand, says Natarajan. In public health, he argues, the real measure isn't price, but cost-effectiveness, especially when early detection can avert far greater globally approved diagnostics protocols remain out of reach in India. The WHO-recommended urine TBLAM test, used to diagnose TB in HIVpositive patients, is still unavailable in the country, despite successful validation studies in Mumbai in 2022. Registration barriers and lack of supply from manufacturers have led to lack of access, says Leena Menghaney, a public health lawyer based in Delhi. Supplyrelated issues could be because trials in India have yet to conclude, according to industry delays cost precious lives. Late detection risks high transmission rates and complications for patients. Dr Jennifer Furin, infectious diseases clinician, Harvard Medical School, says while Truenat is helpful and the diagnostic pipeline is robust, the outdated and slow systems for approving novel tools in India have a detrimental impact. Furin points to a critical gap: the lack of household-level prevention. Studies, including a 2023 trial published in TheLancet, show that modest nutritional support for families of TB patients can sharply reduce transmission. Another model, published in TheLancet this year, estimates that improving household nutrition alone could prevent nearly 5% of TB deaths by carrying the world's highest TB burden, regulatory reforms have been slow in India. Some gains have been made, but systemic delays continue to blunt the impact of new patients with drug-resistant TB, a new wave of treatment offers hope, but conditions apply. Regimens like a six-month, all-oral combination termed BPaLM— bedaquiline, pretomanid, linezolid and moxifloxacin—have been game-changers, replacing the gruelling 24-month regimens of daily injections and pills. 'These regimens are better tolerated and highly effective, with about 90% of people completing treatment successfully,' says clinicians welcome the government's push for shorter regimens, access remains limited—only 1,700 patients in India have received them, according to Dr Rupak Singla, head of the department of respiratory medicine, National Institute of Tuberculosis and Respiratory Diseases , Delhi, who spoke at the event in Mumbai. Adoption has lagged due to limited access to drug susceptibility testing for newer drugs, which is crucial for choosing an appropriate treatment BPaLM regimen can't be given in cases where more than one organ system is involved or in patients with severe extrapulmonary disease, 'both of which are common in India,' according to Dr Alpa Dalal, head of unit, Group of TB Hospitals, Sewri, Mumbai. BPaLM should not be prescribed for patients previously treated with bedaquiline, says Dalal, unless drug susceptibility to bedaquiline and linezolid is says even in extensive pulmonary TB, where studies have shown good outcomes with BPaLM, many clinicians are cautious. In longer regimens, patients with extensive lung involvement have had higher relapse rates, compared with patients with limited disease, she explains, and that concern carries over. A study published in OUP's research platform, Oxford Academic, in March 2025 shows that bedaquiline resistance among previously treated patients can reduce the drug's warn that such resistance could undercut its effectiveness in the long term if not addressed early. But Koul says, 'Bedaquiline has galvanised TB R&D. It will remain a core component of future regimens, unless we see a dramatic rise in resistance in clinical practice.'The economics of care create barriers too. Pricing is a big hurdle. Regimens with imipenem cost thousands of rupees per day. Anushka was treated free by MSF. Else each injection alone, she said, would cost Rs 2,499. Considering the socioeconomic realities of India, perhaps this is where the government could step approach to procurement is problematic too. The country selectively joins pooled procurement platforms like the Global Drug Facility, which could reduce costs. 'India has in the past refused to participate in this, unless they had an emergency,' says policy and procurement, TB is a profoundly social disease, shaped by stigma, poverty and undernutrition. Even the best drugs won't work if care doesn't reach those who need it most. Guidelines may improve and approvals may accelerate but until the system meets people where they are, too many will be left suffered for years before she got cured. Her strength wasn't just in surviving; it was in refusing to give up. 'Even in that condition, I completed my graduation and kept chasing my dreams,' she says. India's TB response must now rise to match that grit, with urgency, equity and compassion.


Hans India
11 hours ago
- Hans India
Bihar: Gaya beneficiary gets free treatment under Ayushman Bharat scheme
Gaya (Bihar): The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY), the world's largest publicly funded health assurance scheme, continues to be a lifeline for countless Indians. Offering free medical treatment worth up to Rs 5 lakh per family annually for secondary and tertiary hospital care, the scheme has emerged as a game-changer in India's healthcare landscape—especially for the poor and lower-middle-class population. In Bihar's Gaya district, the impact of this flagship scheme is evident in the story of Lalan Chaudhary, a farmer originally from Nalanda district. Currently undergoing treatment at Magadh Medical College in Gaya, Lalan is receiving all his medical services—surgery, medicines, accommodation, and food—completely free of cost through his Ayushman Bharat card. Speaking to IANS, Lalan Chaudhary, a beneficiary, said, 'The hips of both my legs were damaged. I've been under treatment for the last one and a half months, and it's all being done free of cost through the Ayushman card. Where would poor people like us get Rs 5 lakh for treatment? We are grateful to Prime Minister Narendra Modi. Medicines, food—everything is taken care of. This is a very good scheme.' Chaudhary learned about the scheme when a government outreach team visited his village. 'They helped us make the Ayushman card at home itself. Now, many people in our village are benefiting from it,' he added. Such personal accounts reflect the broader transformation in India's healthcare ecosystem over the last decade. Through a combination of digitisation, public sector engagement, and targeted welfare initiatives, the Government has brought quality healthcare within reach for millions who previously struggled with high costs and red tape. Crucially, Ayushman Bharat addresses the needs of the "missing middle"—families who neither qualify for traditional subsidies nor can afford costly private insurance. By enabling access to timely hospitalisation and treatment without pushing families into debt, it has shifted the narrative around medical affordability. As of May 30, 2025, more than 41 crore Ayushman cards have been issued across 33 States and Union Territories. These have enabled over 8.5 crore hospital admissions, translating into Rs 1.19 lakh crore worth of treatment covered. A robust network of nearly 32,000 empanelled hospitals, including both public and private facilities, ensures that beneficiaries like Lalan Chaudhary receive uninterrupted medical care. The scheme's reach was further expanded in October 2024, when the Government extended coverage to all senior citizens aged 70 and above, regardless of their income status. This has particularly benefited elderly citizens in the middle-income group, offering peace of mind to families burdened by rising medical expenses. In tandem with Ayushman Bharat, the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) is revolutionising access to affordable medicines. What began with just 80 outlets in 2014 has now grown into a network of 16,469 Jan Aushadhi Kendras. These stores provide high-quality generic medicines at 50-80 per cent lower prices than their branded counterparts, all certified by WHO-GMP standards. Together, these schemes are ushering in a silent but powerful healthcare revolution in India—bridging the gap between policy and people, and turning the right to health into a lived reality.